However, a substantial difference exists in the hypophysitis incidence according to the ICI subclass (anti-CTLA4 mAb versus anti-PD1/PDL1 mAb) and the treatment based on a single ICI or an ICI combination. Here, CTLA4 is linked to hypophysitis.